Vicarious Surgical (RBOT) investor relations material

Executive summary

• Focused on developing a next-generation single-port surgical robotic system for minimally invasive procedures, initially targeting ventral hernia repair.

• Net loss for Q1 2026 was $7.3 million, a 52% improvement from $15.4 million in Q1 2025, driven by significant cost reductions and headcount cuts.

• Operating expenses decreased 52% year-over-year to $7.5 million for Q1 2026.

• Net loss per share (basic and diluted) improved to $1.03 from $2.60 year-over-year.

• Delisted from NYSE in March 2026 due to market capitalization requirements; now quoted on OTCQB, with application pending for Nasdaq listing.

Financial highlights

• Q1 2026 net loss: $7.3 million, down from $15.4 million in Q1 2025.

• Operating expenses were $7.5 million, down from $15.7 million in Q1 2025.

• R&D expenses: $5.0 million (down 46% year-over-year); G&A: $2.1 million (down 60%); S&M: $0.3 million (down 67%).

• Cash and cash equivalents at March 31, 2026: $1.4 million; short-term investments: $2.3 million.

• Accumulated deficit: $253.4 million as of March 31, 2026.

Outlook and guidance

• Current cash and investments expected to fund operations only through Q2 2026, raising substantial doubt about ability to continue as a going concern.

• Full year 2026 cash burn is expected to be $19 million.

• Actively seeking additional equity or debt financing; no assurance of success given market conditions and delisting.

• Plans to pursue FDA authorization and eventual commercialization remain, but timelines and funding are uncertain.